601089 福元医药
已收盘 04-24 15:00:00
资讯
新帖
简况
福元医药(601089)2026年一季报简析:净利润同比下降26.96%
证券之星 · 06:10
福元医药(601089)2026年一季报简析:净利润同比下降26.96%
图解福元医药一季报:第一季度单季净利润同比下降26.96%
证券之星 · 04-24 17:54
图解福元医药一季报:第一季度单季净利润同比下降26.96%
4月24日福元医药跌5.34%,农银医疗保健股票基金重仓该股
证券之星 · 04-24 16:24
4月24日福元医药跌5.34%,农银医疗保健股票基金重仓该股
福元医药最新公告:布瑞哌唑原料药获上市申请批准
证券之星 · 04-23 16:37
福元医药最新公告:布瑞哌唑原料药获上市申请批准
股市必读:福元医药(601089)4月21日披露最新机构调研信息
证券之星 · 04-22
股市必读:福元医药(601089)4月21日披露最新机构调研信息
福元医药最新公告:乙酰半胱氨酸片获得药品注册证书
证券之星 · 04-20
福元医药最新公告:乙酰半胱氨酸片获得药品注册证书
福元医药最新公告:吡格列酮二甲双胍片(Ⅰ)获药品注册证书
证券之星 · 04-20
福元医药最新公告:吡格列酮二甲双胍片(Ⅰ)获药品注册证书
每周股票复盘:福元医药(601089)2025年归母净利润同比下降3.95%
证券之星 · 04-19
每周股票复盘:福元医药(601089)2025年归母净利润同比下降3.95%
股市必读:福元医药年报 - 第四季度单季净利润同比增长7.18%
证券之星 · 04-15
股市必读:福元医药年报 - 第四季度单季净利润同比增长7.18%
福元医药:2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”专项行动方案
证券日报网 · 04-13
福元医药:2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”专项行动方案
福元医药(601089.SH)发布2025年度业绩,归母净利润4.69亿元,同比下降3.95%
智通财经 · 04-13
福元医药(601089.SH)发布2025年度业绩,归母净利润4.69亿元,同比下降3.95%
每周股票复盘:福元医药(601089)艾拉莫德片获注册证书
证券之星 · 04-12
每周股票复盘:福元医药(601089)艾拉莫德片获注册证书
福元医药(601089.SH):艾拉莫德片获得药品注册证书
智通财经 · 04-07
福元医药(601089.SH):艾拉莫德片获得药品注册证书
福元医药(601089.SH):丁二磺酸腺苷蛋氨酸肠溶片获得药品注册证书
智通财经 · 04-07
福元医药(601089.SH):丁二磺酸腺苷蛋氨酸肠溶片获得药品注册证书
每周股票复盘:福元医药(601089)贝美前列素涂剂获临床试验批准
证券之星 · 04-05
每周股票复盘:福元医药(601089)贝美前列素涂剂获临床试验批准
福元医药(601089)披露贝美前列素涂剂获临床试验批准通知书,4月3日股价下跌3.82%
证券之星 · 04-03
福元医药(601089)披露贝美前列素涂剂获临床试验批准通知书,4月3日股价下跌3.82%
福元医药(601089.SH)子公司浙江爱生通过药品GMP现场符合性检查
智通财经 · 03-30
福元医药(601089.SH)子公司浙江爱生通过药品GMP现场符合性检查
福元医药(601089.SH):卡泊三醇搽剂获得药品注册证书
智通财经 · 03-30
福元医药(601089.SH):卡泊三醇搽剂获得药品注册证书
每周股票复盘:福元医药(601089)获二十碳五烯酸乙酯软胶囊注册证
证券之星 · 03-29
每周股票复盘:福元医药(601089)获二十碳五烯酸乙酯软胶囊注册证
福元医药(601089.SH):二十碳五烯酸乙酯软胶囊获得药品注册证书
智通财经 · 03-23
福元医药(601089.SH):二十碳五烯酸乙酯软胶囊获得药品注册证书
加载更多
公司概况
公司名称:
北京福元医药股份有限公司
所属行业:
医药制造业
上市日期:
2022-06-30
主营业务:
北京福元医药股份有限公司的主营业务是药品及医疗器械研发、生产和销售。公司的主要产品是心血管类药品、糖尿病类药品、慢性肾病类药品、消化系统类药品、皮肤病类药品、神经精神系统类药品、妇科类药品、医疗器械。公司是国家认定的高新技术企业,已入选北京医药产业跨越发展工程G20企业,荣列中国药品研发综合实力百强、北京民营企业科技创新百强,中国化药研发实力五十强,建有国家级博士后科研工作站、北京市企业技术中心,通过国家级智能制造能力成熟度三级认证,被评为国家级绿色工厂。
发行价格:
14.62
{"stockData":{"symbol":"601089","market":"SH","secType":"STK","nameCN":"福元医药","latestPrice":20.91,"timestamp":1777014000000,"preClose":22.09,"halted":0,"volume":8301472,"delay":0,"changeRate":-0.0534,"floatShares":480000000,"shares":480000000,"eps":0.9045,"marketStatus":"已收盘","change":-1.18,"latestTime":"04-24 15:00:00","open":21.93,"high":22.08,"low":20.85,"amount":176000000,"amplitude":0.0557,"askPrice":20.92,"askSize":3,"bidPrice":20.91,"bidSize":358,"shortable":0,"etf":0,"ttmEps":0.9045,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.09,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":24.3,"lowLimit":19.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":480000000,"isCdr":false,"pbRate":2.66,"roa":"--","peRate":23.117745,"roe":"2.49%","epsLYR":1,"committee":0.826649,"marketValue":10037000000,"turnoverRate":0.0173,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-04-27。","floatMarketCap":10037000000},"requestUrl":"/m/hq/s/601089","defaultTab":"news","newsList":[{"id":"2630807990","title":"福元医药(601089)2026年一季报简析:净利润同比下降26.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807990?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:10","pubTimestamp":1777155024,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期福元医药发布2026年一季报。根据财报显示,福元医药净利润同比下降26.96%。截至本报告期末,公司营业总收入8.11亿元,同比下降2.32%,归母净利润9541.19万元,同比下降26.96%。去年的净利率为13.45%,算上全部成本后,公司产品或服务的附加值高。持有福元医药最多的基金为农银医疗保健股票,目前规模为11.42亿元,最新净值1.592,较上一交易日下跌0.12%,近一年上涨4.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629812299","title":"图解福元医药一季报:第一季度单季净利润同比下降26.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629812299","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629812299?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:54","pubTimestamp":1777024454,"startTime":"0","endTime":"0","summary":"证券之星消息,福元医药2026年一季报显示,一季度公司主营收入8.11亿元,同比下降2.32%;归母净利润9541.19万元,同比下降26.96%;扣非净利润8950.01万元,同比下降26.72%;负债率21.19%,投资收益517.19万元,财务费用6.92万元,毛利率61.7%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400054025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629161308","title":"4月24日福元医药跌5.34%,农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629161308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629161308?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:24","pubTimestamp":1777019091,"startTime":"0","endTime":"0","summary":"证券之星消息,4月24日福元医药跌5.34%创60日新低,收盘报20.91元,换手率1.73%,成交量8.3万手,成交额1.76亿元。重仓福元医药的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400049635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629280886","title":"福元医药最新公告:布瑞哌唑原料药获上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2629280886","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629280886?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:37","pubTimestamp":1776933425,"startTime":"0","endTime":"0","summary":"福元医药(601089.SH)公告称,公司近日收到国家药监局核准签发的布瑞哌唑原料药《化学原料药上市申请批准通知书》。该原料药用于治疗成人精神分裂症,此前技术审评申请已获受理,目前在CDE原辅包登记信息平台状态为“A”。此次获批将进一步丰富公司产品线,促进公司持续、稳定、健康发展。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300045323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629205070","title":"股市必读:福元医药(601089)4月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2629205070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629205070?lang=zh_cn&edition=full","pubTime":"2026-04-22 04:25","pubTimestamp":1776803112,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘,福元医药报收于22.11元,下跌0.63%,换手率0.55%,成交量2.65万手,成交额5881.77万元。来自:FY101注射液正按计划推进I期临床试验,实验效果符合公司预期。FY101注射液正在推进I期临床实验,实验效果达到预期;FY103注射液于2025年末获境内IND受理。中东局势动荡未对公司生产经营造成直接影响,主营业务集中于国内市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200010623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628440745","title":"福元医药最新公告:乙酰半胱氨酸片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628440745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628440745?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:14","pubTimestamp":1776676457,"startTime":"0","endTime":"0","summary":"福元医药公告称,公司近日收到国家药监局颁发的乙酰半胱氨酸片《药品注册证书》,批准该药品生产。本次获批视同通过一致性评价。截至公告日,公司针对该药品累计研发投入为749.23万元。数据显示,2025年中国三大终端六大市场乙酰半胱氨酸口服常释剂型销售额约为4.10亿元。该药品获得注册证书将进一步丰富公司产品线,有助于提升市场竞争力,但销售情况受政策及市场环境等因素影响,存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628454437","title":"福元医药最新公告:吡格列酮二甲双胍片(Ⅰ)获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628454437","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628454437?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:12","pubTimestamp":1776676365,"startTime":"0","endTime":"0","summary":"福元医药(601089.SH)公告称,公司近日收到国家药监局颁发的吡格列酮二甲双胍片(Ⅰ)《药品注册证书》,批准该药品生产。该药品适用于2型糖尿病患者,视同通过一致性评价。截至公告日,公司针对该药品累计研发投入为579.97万元。数据显示,2025年中国三大终端六大市场吡格列酮二甲双胍片销售额约为19.72亿元。此次获证将进一步丰富公司产品线,有助于提升市场竞争力,但药品销售受政策及市场环境等因素影响,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628389759","title":"每周股票复盘:福元医药(601089)2025年归母净利润同比下降3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628389759","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628389759?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:16","pubTimestamp":1776536171,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,福元医药报收于22.39元,较上周的23.37元下跌4.19%。本周,福元医药4月16日盘中最高价报23.39元。业绩披露要点财务报告福元医药2025年实现主营收入35.04亿元,同比增长1.71%;归母净利润4.69亿元,同比下降3.95%;扣非净利润4.51亿元,同比下降1.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627425659","title":"股市必读:福元医药年报 - 第四季度单季净利润同比增长7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627425659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627425659?lang=zh_cn&edition=full","pubTime":"2026-04-15 01:18","pubTimestamp":1776187090,"startTime":"0","endTime":"0","summary":"截至2026年4月14日收盘,福元医药报收于22.97元,上涨0.04%,换手率0.63%,成交量3.05万手,成交额6931.51万元。来自业绩披露要点:福元医药2025年实现主营收入35.04亿元,同比增长1.71%;归母净利润4.69亿元,同比下降3.95%。股本股东变化股东户数变动近日福元医药披露,截至2026年3月31日公司股东户数为1.88万户,较12月31日减少41.0户,减幅为0.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500002900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627456758","title":"福元医药:2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”专项行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2627456758","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627456758?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:10","pubTimestamp":1776085800,"startTime":"0","endTime":"0","summary":"证券日报网讯4月13日,福元医药发布公告称,公司制定2026年度“提质增效重回报”专项行动方案,具体内容如下:一、持续打造三位一体核心竞争优势;二、积极实施回购方案,重视股东回报;三、重视市值管理,提振市场信心;四、完善公司治理,坚持规范运作;五、持续评估改进行动方案。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437662","title":"福元医药(601089.SH)发布2025年度业绩,归母净利润4.69亿元,同比下降3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437662","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627437662?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:24","pubTimestamp":1776079475,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布2025年年度报告,报告期内,公司实现营业收入35.04亿元,同比增长1.71%。实现归属于上市公司股东的净利润4.69亿元,同比下降3.95%。实现归属于上市公司股东的扣除非经常性损益的净利润4.51亿元,同比下降1.89%。基本每股收益为1元。拟按每10股派发现金红利5.00元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626212259","title":"每周股票复盘:福元医药(601089)艾拉莫德片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626212259","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626212259?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:51","pubTimestamp":1775929870,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,福元医药报收于23.37元,较上周的23.66元下跌1.23%。本周关注点公司公告汇总:艾拉莫德片获药品注册证书,视同通过一致性评价公司公告汇总:艾拉莫德片用于治疗活动性类风湿关节炎,将丰富产品线公司公告汇总:该药品2025年中国市场销售额预计约220,068万元公司公告汇总北京福元医药股份有限公司收到国家药品监督管理局颁发的艾拉莫德片《药品注册证书》,批准该药品生产。艾拉莫德片用于治疗活动性类风湿关节炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625693151","title":"福元医药(601089.SH):艾拉莫德片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693151","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625693151?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:07","pubTimestamp":1775556461,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司收到了国家药品监督管理局颁发的艾拉莫德片(规格:25mg)《药品注册证书》(证书编号:2026S00906),批准该药品生产。由先声药业研制的艾拉莫德片,最早于2011年8月经国家药品监督管理局批准在国内上市,该药品用于治疗活动性类风湿关节炎。公司于2024年10月23日获得申报受理通知书,并于近日获得国家药监局批准。根据国家相关政策规定,本次获得《药品注册证书》,视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625315399","title":"福元医药(601089.SH):丁二磺酸腺苷蛋氨酸肠溶片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625315399","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625315399?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:05","pubTimestamp":1775556355,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司收到了国家药品监督管理局颁发的丁二磺酸腺苷蛋氨酸肠溶片[规格:0.5g(按C₁₅H₂₃N₆O₅S⁺计)]《药品注册证书》(证书编号:2026S00932),批准该药品生产。由ABBOTT研制的丁二磺酸腺苷蛋氨酸肠溶片,1996年11月,经国家药品监督管理局批准,丁二磺酸腺苷蛋氨酸肠溶片在国内上市,本品适用于肝硬化前和肝硬化所致肝内胆汁淤积。该药品适用于妊娠期肝内胆汁淤积。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH):丁二磺酸腺苷蛋氨酸肠溶片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625306619","title":"每周股票复盘:福元医药(601089)贝美前列素涂剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625306619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625306619?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:52","pubTimestamp":1775328731,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,福元医药报收于23.66元,较上周的23.3元上涨1.55%。本周关注点公司公告汇总:贝美前列素涂剂获药物临床试验批准通知书,拟用于治疗睫毛稀少症。公司公告汇总北京福元医药股份有限公司全资子公司福元药业有限公司收到国家药品监督管理局核准签发的贝美前列素涂剂《药物临床试验批准通知书》,同意该药品开展用于治疗睫毛稀少症的临床试验。贝美前列素涂剂尚未在国内获批上市,国内目前仅有贝美前列素滴眼液上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624374651","title":"福元医药(601089)披露贝美前列素涂剂获临床试验批准通知书,4月3日股价下跌3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624374651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624374651?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:07","pubTimestamp":1775210832,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,福元医药报收于23.66元,较前一交易日下跌3.82%,最新总市值为113.57亿元。近日,北京福元医药股份有限公司全资子公司福元药业有限公司收到国家药品监督管理局核准签发的贝美前列素涂剂《药物临床试验批准通知书》,同意该药品开展用于治疗睫毛稀少症的临床试验。贝美前列素涂剂尚未在国内获批上市,国内目前仅有贝美前列素滴眼液上市。本品需完成临床试验并经审批后方可上市,存在研发不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390234","title":"福元医药(601089.SH)子公司浙江爱生通过药品GMP现场符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390234","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623390234?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:44","pubTimestamp":1774860243,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司全资子公司浙江爱生药业有限公司(简称“浙江爱生”)收到药品GMP符合性检查告知书(编号:浙2026第0057号)。检查范围:片剂(激素类):制剂Ⅲ车间,片剂(激素类)Ⅱ生产线。浙江爱生本次通过药品GMP现场符合性检查,表明浙江爱生相关剂型生产线符合GMP要求,有利于公司继续保持稳定的生产能力,满足市场需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390925","title":"福元医药(601089.SH):卡泊三醇搽剂获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623390925?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:42","pubTimestamp":1774860136,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司全资子公司福元药业有限公司(简称“安徽福元”)收到了国家药品监督管理局颁发的卡泊三醇搽剂[规格:0.005%(30ml:1.50mg)]《药品注册证书》(证书编号:2026S00816),批准该药品生产。该药品适用于头皮银屑病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623382853","title":"每周股票复盘:福元医药(601089)获二十碳五烯酸乙酯软胶囊注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2623382853","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623382853?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:36","pubTimestamp":1774726570,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,福元医药报收于23.3元,较上周的22.08元上涨5.53%。本周,福元医药3月27日盘中最高价报23.49元。本周关注点公司公告汇总:二十碳五烯酸乙酯软胶囊获药品注册证书,视同通过一致性评价。公司公告汇总北京福元医药股份有限公司全资子公司浙江爱生药业有限公司收到国家药品监督管理局颁发的二十碳五烯酸乙酯软胶囊《药品注册证书》,批准该药品生产。截至公告日,累计研发投入488.26万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621771190","title":"福元医药(601089.SH):二十碳五烯酸乙酯软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621771190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621771190?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:40","pubTimestamp":1774258819,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司全资子公司浙江爱生药业有限公司(以下简称“浙江爱生”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的二十碳五烯酸乙酯软胶囊(规格:1.0g)《药品注册证书》(证书编号:2026S00777),批准该药品生产。根据米内网数据显示,2025年中国三大终端六大市场二十碳五烯酸乙酯软胶囊的销售额约为4,357万元,其中城市公立医院和县级公立医院销售额为427万元,城市社区中心和乡镇卫生院销售额为3万元,城市实体药店和网上药店销售额为3,927万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH):二十碳五烯酸乙酯软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777162906771,"stockEarnings":[{"period":"1week","weight":-0.0661},{"period":"1month","weight":-0.0594},{"period":"3month","weight":-0.2278},{"period":"6month","weight":-0.0513},{"period":"1year","weight":0.3748},{"period":"ytd","weight":-0.1288}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京福元医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18753人(较上一季度减少0.22%)","perCapita":"25595股","listingDate":"2022-06-30","address":"北京市通州区通州工业开发区广源东街8号","registeredCapital":"48000万元","survey":" 北京福元医药股份有限公司的主营业务是药品及医疗器械研发、生产和销售。公司的主要产品是心血管类药品、糖尿病类药品、慢性肾病类药品、消化系统类药品、皮肤病类药品、神经精神系统类药品、妇科类药品、医疗器械。公司是国家认定的高新技术企业,已入选北京医药产业跨越发展工程G20企业,荣列中国药品研发综合实力百强、北京民营企业科技创新百强,中国化药研发实力五十强,建有国家级博士后科研工作站、北京市企业技术中心,通过国家级智能制造能力成熟度三级认证,被评为国家级绿色工厂。","listedPrice":14.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福元医药,601089,福元医药股票,福元医药股票老虎,福元医药股票老虎国际,福元医药行情,福元医药股票行情,福元医药股价,福元医药股市,福元医药股票价格,福元医药股票交易,福元医药股票购买,福元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}